Beam Therapeutics(BEAM) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Development Progress and Clinical Update Positive initial safety and efficacy data from the Phase 1/2 trial of BEAM-302 were previou ...